Phase II Study Of Nivolumab and Relatlimab In Advanced Mismatch Repair Deficient Cancers Resistant To Prior PD-(L)1 Inhibitor, Including Pancreatic Cancer
The purpose of this phase II study is to evaluate the safety and efficacy of Nivolumab and Relatimab in patients with microsatellite instability high (MSI-H) solid tumors, including pancreatic cancer prior to receiving PD-(L)1 therapy.
Study ID: J18102
Trial Phase: Phase II
Trial Sponsor: Sidney Kimmel Comprehensive Cancer Center
Therapies Used in This Trial: Nivolumab, Relatinib